Neural chip decodes interactions between brain regions

Deep brain stimulation (DBS) is a therapeutic technique that delivers electrical pulses to specific areas of the brain via an implant to modulate neural activity. It is already widely used for movement disorders such as Parkinson’s disease, and researchers are increasingly exploring its potential for severe psychiatric illnesses including major depression, post-traumatic stress disorder, and obsessive-compulsive disorder.

However, most existing DBS systems operate in what engineers call an “open loop” manner: stimulation is delivered according to predefined settings rather than continuously adapting to the patient’s brain activity. Even among closed-loop, or adaptive systems, many rely on signals recorded from a single brain region. This is a major limitation for psychiatric disorders, where clinically relevant information may be distributed across networks of interacting brain regions.

“Our work is based on the growing body of research suggesting that psychiatric disorders arise more from disruptions in communication between brain regions than from dysfunction of any single region,” explains Mahsa Shoaran, head of the Integrated Neurotechnologies Lab in EPFL’s School of Engineering and Neuro-X Institute.

Shoaran says that major challenge was achieving all this functionality while working within the very limited power budget of an implantable system.

“Our entire system is co-designed, meaning the algorithms and hardware are developed together with the constraints of implant in mind. This approach helped us achieve network-level neural signal processing and decoding on a single chip, while keeping power consumption under 200 microwatts — a fraction of that typically required by many implantable neural-interface systems,” she says. Another innovation is LogSync’s use of logarithmic computations, which simplify the complex operations needed for brain-network analysis and real-time biomarker extraction and decoding.

LogSync's initial validation focused on psychiatric applications. But the capability to extract brain-network biomarkers to trigger precisely timed stimulation is broadly applicable across next-generation neurotechnology, including adaptive DBS for movement disorders, closed-loop non-invasive stimulation, and emerging focused-ultrasound interfaces.

In parallel, the laboratory is developing new machine-learning methods that learn directly from neural recordings rather than predefined biomarkers. Their recent ICML 2026 work, which uses self-supervised learning to capture neural activity across regions, channels, and time, supports broader efforts to bring intelligent neural interfaces closer to clinical applications, including through Infera Neuro, an EPFL spin-off co-founded by Shoaran.